Guardian Pharmacy Services earnings release, May 6, 2026

Guardian Pharmacy Services, Inc. (GRDN) · Form 8-K, Item 2.02 · Filed · SEC filing

Guardian Pharmacy Services Reports First Quarter 2026 Financial Results; Updates Full-Year Guidance

ATLANTA, May 6, 2026 – Guardian Pharmacy Services, Inc. (NYSE: GRDN), one of the nation’s leading long-term care (“LTC”) pharmacy services companies, announced today its financial results for the first quarter ended March 31, 2026. The Company also updated its full-year guidance.

First Quarter Financial Results

CEO Commentary

“Our first quarter results reflect a strong start to the year and, importantly, a successful transition into a fundamentally new operating environment.

While the Inflation Reduction Act (the “IRA”) introduced significant pricing resets on certain branded medications that we dispense, we were able to offset the profitability impact, enabling us to maintain margin stability and deliver double-digit Adjusted EBITDA growth. Just as importantly, the underlying fundamentals of the business remain solid, with 10% growth in residents served and prescription volumes,” said Fred P. Burke, President & CEO.

Burke continued, “As the industry adapts to the broader effects of the IRA, we believe our scale, local operating model, and financial strength position us well to navigate ongoing changes and continue delivering consistent service to residents and our facility partners.”

FY 2026 Outlook – Updating Guidance

The updated guidance reflects the pass through of $3 million in discrete benefits, primarily related to a manufacturer inventory credit associated with the IRA, and favorable payor dynamics. The guidance below excludes future acquisitions.

Capital Markets

In March 2026, Guardian completed a non-dilutive, upsized secondary offering of 6.9 million shares of

Guardian’s Class A common stock (including the full exercise of the underwriters’ option). This transaction significantly increased our public float, enhanced trading liquidity, and expanded our institutional investor base. Guardian did not retain any proceeds, and there was no change to the total number of shares of Class A common stock outstanding.

As we fully utilized the capacity under our prior shelf registration statement, today we filed a new shelf registration statement to maintain flexibility to undertake additional offerings in the future. At this time, we do not have any current plans to utilize the shelf.

Conference Call Details

Guardian will host a conference call to discuss these results today at 4:30 pm ET. The call can be accessed live by dialing +1 (833)

461-5787 for participants located in the United States and Canada, or +1 (585)

542-9983 for international participants, and referencing conference ID “621845633.” A webcast replay will be available shortly after the call’s completion at https://investors.guardianpharmacy.com

About Guardian Pharmacy Services

Guardian Pharmacy

Services is one of the nation’s leading long-term care pharmacy services companies. Through its locally-based business model, Guardian partners with long-term care facilities (“LTCFs”) to deliver medications and a comprehensive suite of technology-enabled services designed to enhance care and improve adherence to drug regimens, helping to reduce the cost of care and improve clinical outcomes. With a growing network of more than 61 licensed pharmacies, 54 of which are full-service, Guardian is dedicated to providing exceptional service to approximately 207,000 residents (as of March 31, 2026).

Investor Contact:

Ashley Stockton, Vice President, Investor Relations

IR@guardianpharmacy.net

Financial statements

Income Statement

Three Months Ended March 31, — (UNAUDITED) (In thousands, except per share amounts)

Three Months Ended March 31, – 2025Three Months Ended March 31, – 2026
Revenues329,308336,595
Cost of goods sold264,959260,286
Gross profit64,34976,309
Selling, general, and administrative expenses51,34458,634
Operating income13,00517,675
Other expenses (income):Interest expense170154
Other expenses (income):Other expense (income), net-271-772
Other expenses (income):Total other expenses (income)-101-618
Other expenses (income):Income before income taxes13,10618,293
Other expenses (income):Provision for income taxes3,8334,749
Other expenses (income):Net income9,27313,544
Other expenses (income):Less net income (loss) attributable to non-controlling interests-175249
Other expenses (income):Net income attributable to Guardian Pharmacy Services, Inc.9,44813,295
Net income per share of Class A and Class B common stockBasic0.150.21
Net income per share of Class A and Class B common stockDiluted0.150.21
Weighted-average Class A and Class B common shares outstandingBasic62,04363,321
Weighted-average Class A and Class B common shares outstandingDiluted62,91463,692

Income Statement

Three Months Ended March 31, — (UNAUDITED) (in thousands)

Three Months Ended March 31, – 2025Three Months Ended March 31, – 2026
Net income9,27313,544
Add:Interest expense (income), net-2-416
Add:Depreciation and amortization5,2675,976
Add:Provision for income taxes3,8334,749
Add:EBITDA18,37123,853
Add:Share-based compensation (1)3,9681,861
Add:Certain legal & other regulatory matters (2)28-71
Add:Financing-related and other activities (3)798841
Add:Payor-reimbursement matters (4)2683,274
Add:Adjusted EBITDA23,43329,758
Add:Net income as a percentage of revenue2.8%4.0%
Add:Adjusted EBITDA as a percentage of revenue7.1%8.8%
Add:Net Income attributable to Guardian Pharmacy Services, Inc.9,44813,295
Add:Share-based compensation (1)3,9681,861
Add:Certain legal & other regulatory matters (2)28-71
Add:Financing-related and other activities (3)798841
Add:Payor-reimbursement matters (4)2683,274
Add:Acquisition-related intangible asset amortization (5)835992
Add:Income tax impact of adjustments (6)-1,722-1,790
Add:Adjusted net income13,62318,402
Add:Weighted average common shares outstanding used in calculating diluted U.S. GAAP net income per share62,91463,692
Add:Weighted average common shares outstanding used in calculating diluted Non-GAAP net income per share62,91463,692
Add:Diluted EPS0.150.21
Add:Adjusted EPS0.220.29

Balance Sheet

December 31, 2025 — (UNAUDITED) (In thousands, except share amounts)

December 31, 2025March 31, 2026
Current assets:Cash and cash equivalents65,61964,893
Current assets:Accounts receivable, net101,614111,704
Current assets:Inventories43,35947,159
Current assets:Other current assets11,04211,428
Current assets:Total current assets221,634235,184
Current assets:Property and equipment, net55,52256,620
Current assets:Intangible assets, net18,47517,482
Current assets:Goodwill79,74379,743
Current assets:Operating lease right-of-use assets34,64934,268
Current assets:Deferred tax assets2,1992,199
Current assets:Other assets4361,445
Current assets:Total assets412,658426,941
Current liabilities:Accounts payable116,206108,552
Current liabilities:Accrued compensation15,04812,790
Current liabilities:Operating leases, current portion7,1507,220
Current liabilities:Other current liabilities22,29931,981
Current liabilities:Total current liabilities160,703160,543
Current liabilities:Operating leases, net of current portion29,99229,665
Current liabilities:Other liabilities4,0394,309
Current liabilities:Total liabilities194,734194,517
Equity:Class A common stock - 700,000,000 shares authorized, par value $0.001; 36,253,744 and 49,781,181 shares issued and outstanding as of December 31, 2025 and March 31, 2026, respectively3650
Equity:Class B common stock - 100,000,000 shares authorized, par value $0.001; 27,066,890 and 13,539,453 shares issued and outstanding as of December 31, 2025 and March 31, 2026, respectively2713
Equity:Additional paid-in capital139,353141,190
Equity:Retained earnings66,34379,638
Equity:Non-controlling interests12,16511,533
Equity:Total equity217,924232,424
Equity:Total liabilities and equity412,658426,941

Cash Flow

Three Months Ended March 31, — CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (in thousands)

Three Months Ended March 31, – 2025Three Months Ended March 31, – 2026
Operating activitiesNet income9,27313,544
Adjustments to reconcile net income to net cash provided by operating activities:Depreciation and amortization5,2675,976
Adjustments to reconcile net income to net cash provided by operating activities:Share-based compensation expense3,9681,861
Adjustments to reconcile net income to net cash provided by operating activities:Provision for losses on accounts receivable8961,062
Adjustments to reconcile net income to net cash provided by operating activities:Other-141-79
Changes in operating assets and liabilities:Accounts receivable-1,007-11,129
Changes in operating assets and liabilities:Inventories-2,881-3,800
Changes in operating assets and liabilities:Other current assets-1,588-1,394
Full release

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements are all statements other than those of historical fact. Any statements about our expectations, beliefs, plans, predictions, forecasts, objectives, assumptions, or future events or performance are forward-looking. These statements are often, but not always, made through the use of words such as “aims,”

“anticipates,” “believes,” “continue,” “estimates,” “expects,” “intends,” “may,” “outlook,” “plans,” “projects,”

“seeks,” “should,” “will,” “would,” and similar expressions. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements are not guarantees of future performance and involve risks and uncertainties which are subject to change based on various important factors, many of which are beyond our control. Such risks and uncertainties include: our ability to effectively execute our business strategies, implement new initiatives and improve efficiency; our ability to effectively market and sell, customer acceptance of, and competition for, our pharmaceutical and health care services in new and existing markets; our relationships with pharmaceutical wholesalers and key manufacturers, LTCFs and health plan payors; our ability to maintain and expand relationships with LTCF operators on favorable terms; the impact of a national emergency, public health crisis, global pandemic or outbreak of infectious disease on our employees and business and on our supply chain and the LTCFs we serve; continuing government and private efforts to lower pharmaceutical costs, including by capping the prices for certain drugs and limiting pharmacy reimbursements; changes in, and our ability to comply with, healthcare and other applicable laws, regulations or interpretations; further consolidation of managed care organizations and other health plan payors and changes in the terms of our agreements with these parties; our ability to retain members of our senior management team, our local pharmacy management teams and our pharmacy professionals; our exposure to, and the results of, claims, legal proceedings and governmental... (truncated)ttacks); product liability, product recall, personal injury or other health and safety issues related to the pharmaceuticals we dispense; the impact of supply chain and other manufacturing disruptions or trade policies related to the pharmaceuticals we dispense; the sufficiency of our sources of liquidity and financial resources to fund our future operating expenses and capital expenditure requirements, and our ability to raise additional capital, if needed; and the misuse or off-label use, or errors in the dispensing or administration, of the pharmaceuticals we dispense. We are subject to additional risks and uncertainties described in our periodic reports filed with the Securities and Exchange Commission from time to time, including in the “Risk Factors” section contained in our most recent Annual Report on Form

10-K, which report is publicly available at www.sec.gov and via our website, investors.guardianpharmacy.com Any forward-looking statements in this press release should be evaluated in light of these important risk factors. This press release reflects management’s views as of the date hereof. Except to the extent required by applicable law, Guardian undertakes no obligation to update or revise any information contained in this press release beyond the published date, whether as a result of new information, future events or otherwise.

Additional Information

This release should be read in conjunction with the consolidated financial statements and notes thereto included in our most recent Annual Report on Form

10-K,

Quarterly Report on Form

10-Q and subsequent filings. Copies of our reports are available on our website at no expense at investors.guardianpharmacy.com and through the

SEC’s website at www.sec.gov.

Use of

Non-GAAP

Financial Measures

To supplement the results presented in our consolidated financial statements in accordance with GAAP, we also present Adjusted EBITDA, Adjusted

Net Income, and Adjusted EPS, which are financial measures not based on any standardized methodology prescribed by GAAP.

We define

Adjusted EBITDA as net income before interest expense, income taxes, depreciation and amortization, as adjusted to exclude the impact of items and amounts that we view as not indicative of our core operating performance, including share-based compensation expense, certain legal and regulatory items, financing-related and other activities, and payor-reimbursement matters.

We define Adjusted Net Income as net income attributable to Guardian Pharmacy Services, Inc. before share-based compensation expense, certain legal and other regulatory items, financing-related and other activities, payor-reimbursement matters, amortization expense associated with acquisition-related intangible assets, and the income tax impact of the adjustments.

We define

Adjusted EPS as Adjusted Net Income divided by the total weighted average of diluted shares for Class A common stock and Class B common stock.

Adjusted EBITDA, Adjusted Net Income, and Adjusted EPS do not have a definition under GAAP, and our definition of Adjusted EBITDA, Adjusted

Net Income, and Adjusted EPS may not be the same as, or comparable to, similarly titled measures used by other companies.

We use Adjusted

EBITDA, Adjusted Net Income, and Adjusted EPS to better understand and evaluate our core operating performance and trends. We believe that presenting Adjusted EBITDA, Adjusted Net Income, and Adjusted EPS provides useful information to investors in understanding and evaluating our operating results, as it permits investors to view our core business performance using the same metrics that management uses to evaluate our performance.

There are a number of limitations related to the use of Adjusted EBITDA, Adjusted Net Income, and Adjusted EPS rather than the most directly comparable GAAP financial measure, including:

Because of these limitations, Adjusted EBITDA, Adjusted Net Income, and Adjusted EPS should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. You should consider Adjusted EBITDA, Adjusted Net Income, and Adjusted EPS alongside other financial measures, including net income, diluted EPS, and our other financial results presented in accordance with GAAP.

A reconciliation of Adjusted EBITDA to net income and of Adjusted Net Income to Net Income Attributable to Guardian Pharmacy Services, Inc., the most directly comparable GAAP financial measures, are set forth below.

Guardian has not provided a quantitative reconciliation of forecasted adjusted EBITDA, which is a non-GAAP financial measure, to forecasted net income within this release because Guardian is unable, without making unreasonable efforts, to calculate certain reconciling items with confidence due to the variability and complexity of such items. These items include, but are not limited to, income taxes and share-based compensation. These items, which could materially affect the computation of forecasted net income, are inherently uncertain and depend on various factors that are not estimable at this time.

GUARDIAN PHARMACY SERVICES, INC. AND SUBSIDIARIES

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Guardian Pharmacy Services earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.